UNSPSC 51385404: Cinchophen lithium

This classification denotes a nonsteroidal antiinflammatory drug C16H10NO2.Li, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17Z71O8Z3D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, lithium salt (1:1), but more generally known as cinchophen lithium, which bears US NIH Compound Identifier 71300649. European Medicines Agency schedules Cinchophen lithium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01307MIG.

Most nations, for tariff and trade purposes, schedule cinchophen lithium under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN LITHIUM remains US FDA's Preferred Term for this commodity. SMILES: [LI+].C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)[O-].

UNSPSC 51385404 Cinchophen lithium is a Commodity code that shows limited recent state and local procurement activity aligned with its nominal scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS—tags naloxone and drug deactivation systems procurement under this code, a clear mismatch with cinchophen lithium, a pharmaceutical compound with distinct clinical uses. The opportunity itself involves acquisition of 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, delivered quarterly to Seminole County Community Health Building in Sanford, Florida. This code does not reflect active, well-aligned state and local procurement for cinchophen lithium products or related pharmaceutical commodities at this time.

Seminole County, a Florida county government, represents the only issuing body with recent activity tagged to this code. The naloxone procurement was released as an IFB on July 10, 2023, with a response deadline of July 26, 2023, at 2:00 pm, though the posting date of June 30, 2026, suggests a data integrity issue in the source record. The contract offered an initial two-year term with an optional one-year renewal, required electronic bid submission through the county's e-procurement portal, and included standard compliance provisions for drug-free workplace certification, E-Verify authorization, and specified insurance coverages. The procurement noted potential FEMA funding and associated federal compliance requirements. The substantial mismatch between the code's pharmaceutical classification and the naloxone-focused scope indicates this code warrant careful vendor research to confirm actual state and local demand for cinchophen lithium products before resource allocation.